Mohamad Navab

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12069837/publications.pdf

Version: 2024-02-01

166 papers	21,646 citations	9786 73 h-index	8866 145 g-index
167 all docs	167 docs citations	167 times ranked	15466 citing authors

#	Article	IF	Citations
1	Atherosclerosis: Basic Mechanisms. Circulation, 1995, 91, 2488-2496.	1.6	1,387
2	Antiinflammatory Properties of HDL. Circulation Research, 2004, 95, 764-772.	4.5	1,170
3	Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998, 394, 284-287.	27.8	1,017
4	Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo. Journal of Biological Chemistry, 1997, 272, 13597-13607.	3.4	691
5	Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Journal of Lipid Research, 2004, 45, 993-1007.	4.2	585
6	The Yin and Yang of Oxidation in the Development of the Fatty Streak. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 831-842.	2.4	553
7	Ambient Particulate Pollutants in the Ultrafine Range Promote Early Atherosclerosis and Systemic Oxidative Stress. Circulation Research, 2008, 102, 589-596.	4.5	551
8	Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment. Circulation, 2003, 108, 2751-2756.	1.6	545
9	HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology, 2011, 8, 222-232.	13.7	506
10	Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. Journal of Lipid Research, 2000, 41, 1481-1494.	4.2	423
11	Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein. Journal of Biological Chemistry, 2001, 276, 44444-44449.	3.4	404
12	Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol. Circulation, 2002, 105, 290-292.	1.6	400
13	HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 481-488.	2.4	391
14	Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 2541-2549.	6.7	360
15	Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. Journal of Lipid Research, 2000, 41, 1495-1508.	4.2	353
16	Oral D-4F Causes Formation of Pre-Î² High-Density Lipoprotein and Improves High-Density Lipoproteinâ€“Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein Eâ€“Null Mice. Circulation, 2004, 109, 3215-3220.	1.6	325
17	Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 542-547.	2.4	319
18	Pulsatile Versus Oscillatory Shear Stress Regulates NADPH Oxidase Subunit Expression. Circulation Research, 2003, 93, 1225-1232.	4.5	300

#	Article	IF	Citations
19	High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection. Circulation, 2001, 103, 2283-2288.	1.6	297
20	A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. Journal of Lipid Research, 2001, 42, 1308-1317.	4.2	292
21	Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. Journal of Lipid Research, 2008, 49, 1344-1352.	4.2	266
22	The paraoxonase gene family and atherosclerosis. Free Radical Biology and Medicine, 2005, 38, 153-163.	2.9	255
23	High-Density Lipoprotein Function. Journal of the American College of Cardiology, 2005, 46, 1792-1798.	2.8	254
24	Apolipoprotein A-I Mimetic Peptides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1325-1331.	2.4	246
25	Role of Group II Secretory Phospholipase A₂in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1284-1290.	2.4	236
26	Mechanisms of Disease: proatherogenic HDLâ€"an evolving field. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 504-511.	2.8	210
27	NOTCH1 is a mechanosensor in adult arteries. Nature Communications, 2017, 8, 1620.	12.8	205
28	Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. Journal of Lipid Research, 2001, 42, 1096-1104.	4.2	203
29	Structural Identification of a Novel Pro-inflammatory Epoxyisoprostane Phospholipid in Mildly Oxidized Low Density Lipoprotein. Journal of Biological Chemistry, 1999, 274, 24787-24798.	3.4	190
30	The role of dysfunctional HDL in atherosclerosis. Journal of Lipid Research, 2009, 50, S145-S149.	4.2	185
31	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19997-20002.	7.1	184
32	Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. Journal of Lipid Research, 2008, 49, 2302-2311.	4.2	181
33	Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide. Circulation, 2002, 106, 1127-1132.	1.6	177
34	Paraoxonase and coronary heart disease. Current Opinion in Lipidology, 1998, 9, 319-324.	2.7	177
35	Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation. Circulation Research, 2005, 97, 763-771.	4.5	165
36	On the physiological role(s) of the paraoxonases. Chemico-Biological Interactions, 1999, 119-120, 379-388.	4.0	163

#	Article	IF	Citations
37	Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes. Diabetes, 2011, 60, 2617-2623.	0.6	162
38	Paraoxonase 2 Deficiency Alters Mitochondrial Function and Exacerbates the Development of Atherosclerosis. Antioxidants and Redox Signaling, 2011, 14, 341-351.	5.4	151
39	Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins. Journal of Biological Chemistry, 2006, 281, 29491-29500.	3.4	149
40	Role of Group II Secretory Phospholipase A 2 in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1291-1298.	2.4	148
41	Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. Journal of Clinical Investigation, 2008, 118, 2917-2928.	8.2	146
42	D-4F and Statins Synergize to Render HDL Antiinflammatory in Mice and Monkeys and Cause Lesion Regression in Old Apolipoprotein Eâ€“Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1426-1432.	2.4	145
43	The Role of High-Density Lipoproteins in Oxidation and Inflammation. Trends in Cardiovascular Medicine, 2001, 11, 155-161.	4.9	139
44	A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. Journal of Lipid Research, 2001, 42, 545-552.	4.2	138
45	The Role of High-Density Lipoprotein in Inflammation. Trends in Cardiovascular Medicine, 2005, 15, 158-161.	4.9	136
46	Monocyte recruitment to endothelial cells in response to oscillatory shear stress. FASEB Journal, 2003, 17, 1648-1657.	0.5	135
47	Pathogenesis of atherosclerosis. American Journal of Cardiology, 1995, 76, 18C-23C.	1.6	134
48	The double jeopardy of HDL. Annals of Medicine, 2005, 37, 173-178.	3.8	131
49	Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. Journal of Lipid Research, 2011, 52, 361-373.	4.2	129
50	HDL metabolism and activity in chronic kidney disease. Nature Reviews Nephrology, 2010, 6, 287-296.	9.6	128
51	Diesel Exhaust Induces Systemic Lipid Peroxidation and Development of Dysfunctional Pro-Oxidant and Pro-Inflammatory High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1153-1161.	2.4	127
52	D-4F, an Apolipoprotein A-I Mimetic Peptide, Inhibits the Inflammatory Response Induced by Influenza A Infection of Human Type II Pneumocytes. Circulation, 2004, 110, 3252-3258.	1.6	121
53	An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein Eâ€“Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1932-1937.	2.4	117
54	Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 540-547.	3.3	117

#	Article	IF	Citations
55	Estradiol Suppresses MCP-1 Expression In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1575-1582.	2.4	115
56	Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. Journal of Lipid Research, 2007, 48, 1915-1923.	4.2	112
57	Oxidized Lipids in Atherogenesis: Formation, Destruction and Action. Thrombosis and Haemostasis, 1997, 78, 195-199.	3.4	108
58	Oxidized Phospholipids Induce Changes in Hepatic Paraoxonase and ApoJ but Not Monocyte Chemoattractant Protein-1 via Interleukin-6. Journal of Biological Chemistry, 2001, 276, 1923-1929.	3.4	107
59	Hemoglobin and Its Scavenger Protein Haptoglobin Associate with ApoA-1-containing Particles and Influence the Inflammatory Properties and Function of High Density Lipoprotein. Journal of Biological Chemistry, 2009, 284, 18292-18301.	3.4	103
60	Structure and Function of HDL Mimetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 164-168.	2.4	102
61	Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. Journal of Lipid Research, 2007, 48, 2344-2353.	4.2	101
62	In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney International, 2009, 76, 437-444.	5.2	98
63	HDL as a Biomarker, Potential Therapeutic Target, and Therapy. Diabetes, 2009, 58, 2711-2717.	0.6	97
64	Inflammation and metabolic disorders. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 459-464.	2.5	95
65	Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice. Journal of Lipid Research, 2013, 54, 1608-1615.	4.2	95
66	Oxidized lipids as mediators of coronary heart disease. Current Opinion in Lipidology, 2002, 13, 363-372.	2.7	94
67	High-density lipoprotein: Antioxidant and anti-inflammatory properties. Current Atherosclerosis Reports, 2007, 9, 244-248.	4.8	88
68	A novel approach to oral apoA-I mimetic therapy. Journal of Lipid Research, 2013, 54, 995-1010.	4.2	86
69	Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis. Journal of Experimental Medicine, 2015, 212, 2147-2163.	8.5	86
70	Apolipoprotein A-I mimetic peptides. Current Atherosclerosis Reports, 2009, 11, 52-57.	4.8	82
71	Oral Small Peptides Render HDL Antiinflammatory in Mice and Monkeys and Reduce Atherosclerosis in ApoE Null Mice. Circulation Research, 2005, 97, 524-532.	4.5	81
72	Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Molecular Genetics and Metabolism, 2006, 89, 368-373.	1.1	80

#	Article	IF	Citations
73	Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p. Circulation, 2014, 130, 776-785.	1.6	80
74	Short-Term Feeding of Atherogenic Diet to Mice Results in Reduction of HDL and Paraoxonase That May Be Mediated by an Immune Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1946-1952.	2.4	74
75	Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Current Opinion in Lipidology, 2004, 15, 645-649.	2.7	74
76	High density associated enzymes: their role in vascular biology. Current Opinion in Lipidology, 1998, 9, 449-456.	2.7	73
77	Aromatic Residue Position on the Nonpolar Face of Class A Amphipathic Helical Peptides Determines Biological Activity. Journal of Biological Chemistry, 2004, 279, 26509-26517.	3.4	72
78	Understanding Changes in High Density Lipoproteins During the Acute Phase Response. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1687-1688.	2.4	72
79	Endothelial Cell Dynamics under Pulsating Flows: Significance of High Versus Low Shear Stress Slew Rates. Annals of Biomedical Engineering, 2002, 30, 646-656.	2.5	71
80	A biochemical fluorometric method for assessing the oxidative properties of HDL. Journal of Lipid Research, 2011, 52, 2341-2351.	4.2	70
81	Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein Eâ€“Null Mice. Circulation, 2003, 108, 1735-1739.	1.6	69
82	Differential Association of Hemoglobin with Proinflammatory High Density Lipoproteins in Atherogenic/Hyperlipidemic Mice. Journal of Biological Chemistry, 2007, 282, 23698-23707.	3.4	69
83	D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. Journal of Lipid Research, 2006, 47, 2148-2160.	4.2	66
84	Apolipoprotein A-I Mimetic Peptides Prevent Atherosclerosis Development and Reduce Plaque Inflammation in a Murine Model of Diabetes. Diabetes, 2010, 59, 3223-3228.	0.6	66
85	Ambient Ultrafine Particle Ingestion Alters Gut Microbiota in Association with Increased Atherogenic Lipid Metabolites. Scientific Reports, 2017, 7, 42906.	3.3	66
86	L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integrative Biology (United Kingdom), 2011, 3, 479.	1.3	65
87	HDL Mimetics Inhibit Tumor Development in Both Induced and Spontaneous Mouse Models of Colon Cancer. Molecular Cancer Therapeutics, 2012, 11, 1311-1319.	4.1	63
88	High-Density Lipoprotein and 4F Peptide Reduce Systemic Inflammation by Modulating Intestinal Oxidized Lipid Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2553-2560.	2.4	62
89	High-Density Lipoprotein Cholesterol. Stroke, 2007, 38, 1104-1109.	2.0	61
90	Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. Journal of Lipid Research, 2011, 52, 1200-1210.	4.2	61

#	Article	IF	Citations
91	Dâ€4F, an apoAâ€‐mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. International Journal of Cancer, 2012, 130, 1071-1081.	5.1	61
92	Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. Journal of Lipid Research, 2013, 54, 3403-3418.	4.2	60
93	Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells. Circulation Research, 2020, 127, 1552-1565.	4.5	60
94	All ApoB-Containing Lipoproteins Induce Monocyte Chemotaxis and Adhesion When Minimally Modified. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1437-1446.	2.4	59
95	Pulsatile Flow Regulates Monocyte Adhesion to Oxidized Lipid-Induced Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1770-1776.	2.4	59
96	PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. Journal of Lipid Research, 2004, 45, 1852-1858.	4.2	59
97	Adenovirus-Mediated Expression of Human Paraoxonase 3 Protects Against the Progression of Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1368-1374.	2.4	58
98	Oral Apolipoprotein Aâ€‐Mimetic Dâ€4F Lowers HDLâ€‐Inflammatory Index in Highâ€‐Risk Patients: A Firstâ€‐inâ€‐Human Multipleâ€‐Dose, Randomized Controlled Trial. Clinical and Translational Science, 2017, 10, 455-469.	3.1	56
99	A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. Journal of Lipid Research, 2009, 50, 1538-1547.	4.2	55
100	D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. Journal of Lipid Research, 2012, 53, 437-445.	4.2	55
101	L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in more Anti-Inflammatory HDL in Mice. Drug Metabolism Letters, 2010, 4, 139-148.	0.8	50
102	D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. Journal of Lipid Research, 2008, 49, 192-205.	4.2	49
103	Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease. Current Pharmaceutical Design, 2011, 17, 17-20.	1.9	49
104	Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clinical Immunology, 2008, 127, 234-244.	3.2	48
105	Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Research and Therapy, 2010, 12, R93.	3.5	47
106	Mitogen-activated Protein Kinase Phosphatase 1 Activity Is Necessary for Oxidized Phospholipids to Induce Monocyte Chemotactic Activity in Human Aortic Endothelial Cells. Journal of Biological Chemistry, 2001, 276, 17030-17035.	3.4	46
107	Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis. Journal of Lipid Research, 2015, 56, 871-887.	4.2	41
108	Dysfunctional High-Density Lipoprotein and the Potential of Apolipoprotein A-1 Mimetic Peptides to Normalize the Composition and Function of Lipoproteins. Circulation Journal, 2011, 75, 1533-1538.	1.6	39

#	Article	IF	Citations
109	Apolipoprotein A-I Mimetic Peptides Inhibit Expression and Activity of Hypoxia-Inducible Factor-1Î± in Human Ovarian Cancer Cell Lines and a Mouse Ovarian Cancer Model. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 255-262.	2.5	39
110	Apolipoprotein A-I mimetics. Current Opinion in Lipidology, 2014, 25, 304-308.	2.7	39
111	Proinflammatory Highâ€Density Lipoprotein Results from Oxidized Lipid Mediators in the Pathogenesis of Both Idiopathic and Associated Types of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 640-648.	1.7	37
112	ATP-Binding Cassette Transporter 1 Participates in LDL Oxidation by Artery Wall Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1877-1883.	2.4	36
113	Potential Role for Mitogen-Activated Protein Kinase Phosphatase-1 in the Development of Atherosclerotic Lesions in Mouse Models. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1676-1681.	2.4	35
114	Atmospheric ultrafine particles promote vascular calcification via the NF-Î¹B signaling pathway. American Journal of Physiology - Cell Physiology, 2013, 304, C362-C369.	4.6	35
115	Anti-Inflammatory Properties of HDL. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 351-358.	5.7	34
116	Heart Failure is Associated With Impaired Anti-Inflammatory and Antioxidant Properties of High-Density Lipoproteins. American Journal of Cardiology, 2013, 112, 1770-1777.	1.6	34
117	Modifying the anti-inflammatory effects of high-density lipoprotein. Current Atherosclerosis Reports, 2007, 9, 57-63.	4.8	32
118	Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 274-284.	2.4	31
119	Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer. Scientific Reports, 2018, 8, 9032.	3.3	31
120	Salutary Effects of Hemodialysis on Low-Density Lipoprotein Proinflammatory and High-Density Lipoprotein Anti-inflammatory Properties in Patient With End-Stage Renal Disease. Journal of the National Medical Association, 2011, 103, 524-533.	0.8	30
121	High-density lipoprotein increases intracellular calcium levels by releasing calcium from internal stores in human endothelial cells. Atherosclerosis, 1999, 143, 299-306.	0.8	29
122	The Effect of Apolipoprotein Mimetic Peptides in Inflammatory Disorders Other Than Atherosclerosis. Trends in Cardiovascular Medicine, 2008, 18, 61-66.	4.9	29
123	Apolipoprotein E^{â^'/â^'}Mice Lacking Hemopexin Develop Increased Atherosclerosis via Mechanisms That Include Oxidative Stress and Altered Macrophage Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1152-1163.	2.4	29
124	Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Current Atherosclerosis Reports, 2008, 10, 171-176.	4.8	27
125	L-4F Alters Hyperlipidemic (But Not Healthy) Mouse Plasma to Reduce Platelet Aggregation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 283-289.	2.4	27
126	High-Density Lipoprotein and the Dynamics of Atherosclerotic Lesions. Circulation, 2001, 104, 2386-2387.	1.6	27

#	Article	IF	Citations
127	Apo A-1 Mimetic Peptides as Atheroprotective Agents in Murine Models. Current Drug Targets, 2008, 9, 204-209.	2.1	26
128	HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids in Health and Disease, 2011, 10, 35.	3.0	25
129	Ambient ultrafine particles reduce endothelial nitric oxide production via S-glutathionylation of eNOS. Biochemical and Biophysical Research Communications, 2013, 436, 462-466.	2.1	25
130	Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Current Opinion in Investigational Drugs, 2008, 9, 1157-62.	2.3	25
131	Vasculitis, Atherosclerosis, and Altered HDL Composition in Heme-Oxygenase-1-Knockout Mice. International Journal of Hypertension, 2012, 2012, 1-6.	1.3	24
132	Oral amphipathic peptides as therapeutic agents. Expert Opinion on Investigational Drugs, 2006, 15, 13-21.	4.1	23
133	Identification of genes induced by oxidized phospholipids in human aortic endothelial cells. Vascular Pharmacology, 2002, 38, 211-218.	2.1	22
134	Potential clinical utility of high-density lipoprotein-mimetic peptides. Current Opinion in Lipidology, 2006, 17, 440-444.	2.7	22
135	Peptide mimetics of apolipoproteins improve HDL function. Journal of Clinical Lipidology, 2007, 1, 142-147.	1.5	22
136	Searching for a successful HDL-based treatment strategy. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 162-167.	2.4	22
137	Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids in Health and Disease, 2012, 11, 87.	3.0	21
138	A novel anti-atherogenic role for COX-2â€"potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins and Other Lipid Mediators, 2007, 84, 24-33.	1.9	20
139	Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. Journal of Lipid Research, 2015, 56, 1206-1221.	4.2	20
140	Tg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WD. Journal of Lipid Research, 2016, 57, 832-847.	4.2	20
141	Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Nephrology Dialysis Transplantation, 2010, 25, 3525-3534.	0.7	18
142	Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels. Molecular Genetics and Metabolism, 2010, 101, 66-75.	1.1	17
143	Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma. Journal of Lipid Research, 2011, 52, 1795-1809.	4.2	17
144	Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. Pharmacology Research and Perspectives, 2015, 3, e00154.	2.4	17

#	Article	IF	Citations
145	Small lipidated anti-obesity compounds derived from neuromedin U. European Journal of Medicinal Chemistry, 2015, 101, 616-626.	5.5	17
146	Involvement of Lowâ€Density Lipoprotein Receptor in the Pathogenesis of Pulmonary Hypertension. Journal of the American Heart Association, 2020, 9, e012063.	3.7	16
147	An Apolipoprotein A-I Mimetic Works Best in the Presence of Apolipoprotein A-I. Circulation Research, 2005, 97, 1085-1086.	4.5	14
148	Role of enterocyte stearoyl-Co-A desaturase-1 in LDLR-null mice. Journal of Lipid Research, 2018, 59, 1818-1840.	4.2	14
149	Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Current Opinion in Investigational Drugs, 2003, 4, 1100-4.	2.3	14
150	Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-Î² and cholesterol 25-hydroxylase in jejunum. Journal of Lipid Research, 2017, 58, 1636-1647.	4.2	13
151	The Effect of HDL Mimetic Peptide 4F on PON1. Advances in Experimental Medicine and Biology, 2010, 660, 167-172.	1.6	12
152	Synthetic peptides: managing lipid disorders. Current Opinion in Lipidology, 2006, 17, 233-237.	2.7	11
153	Oxpholipin 11D: An Anti-Inflammatory Peptide That Binds Cholesterol and Oxidized Phospholipids. PLoS ONE, 2010, 5, e10181.	2.5	8
154	Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation. Journal of Lipid Research, 2022, 63, 100153.	4.2	8
155	Dyslipidemia and cardiovascular diseases. Current Opinion in Lipidology, 2009, 20, 157-158.	2.7	4
156	Protective Action of HDL-Associated PON1 Against LDL Oxidation. , 2002, , 125-136.		4
157	ApoA-I Mimetic Peptides: A Review of the Present Status. , 2015, , 15-27.		3
158	Apparent Paradox of Low-Fat â€œHealthyâ€•Diets Increasing Plasma Levels of Oxidized Low-Density Lipoprotein and Lipoprotein(a). Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 392-393.	2.4	2
159	Oxidation hypothesis of atherogenesis: HDL inflammatory index and apolipoprotein A-I mimetic peptides. Future Cardiology, 2007, 3, 309-319.	1.2	2
160	Near Term Prospects for Ameliorating Cardiovascular Aging. , 2010, , 279-306.		1
161	Tobacco Smoke Exposure Reduces Paraoxonase Activity in a Murine Model. International Journal of Biomedical Science, 2017, 13, 20-25.	0.1	1
162	Apolipoprotein A-I Mimetic Peptides. , 2006, , 329-331.		0

#	Article	IF	Citations
163	Reducing plasma cholesterol is not the end of the quest. Atherosclerosis, 2013, 227, 35-36.	0.8	0
164	Enzymes and Proteins that are Associated with High Density Lipoprotein and their Role in the Anti-Inflammatory Capacity of HDL. Medical Science Symposia Series, 1996, , 599-601.	0.0	0
165	Apolipoprotein A-I Mimetic Peptides in Mouse Models of Cancer. , 2015, , 55-62.		0
166	Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis. Journal of Cell Biology, 2015, 211, 2114OIA269.	5.2	0